Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) were up 7.2% during trading on Thursday . The stock traded as high as $6.79 and last traded at $6.73, with a volume of 1,372,300 shares trading hands. The stock had previously closed at $6.28.

A number of research firms have commented on FOLD. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a research note on Monday, July 25th. Robert W. Baird began coverage on Amicus Therapeutics in a research note on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 price objective on the stock. Leerink Swann reissued an “outperform” rating and issued a $19.00 price objective (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Tuesday, June 14th. Bank of America Corp. began coverage on Amicus Therapeutics in a research note on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Chardan Capital set a $15.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $12.19.

The company’s 50 day moving average price is $6.10 and its 200-day moving average price is $6.81. The company’s market capitalization is $852.50 million.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. Analysts expect that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

In other Amicus Therapeutics news, General Counsel Ellen Rosenberg purchased 15,000 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The shares were bought at an average price of $7.67 per share, for a total transaction of $115,050.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jay Barth sold 20,916 shares of Amicus Therapeutics stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $7.00, for a total value of $146,412.00. Following the completion of the transaction, the insider now owns 25,458 shares in the company, valued at approximately $178,206. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. RS Investment Management Co. LLC raised its position in shares of Amicus Therapeutics by 22.0% in the fourth quarter. RS Investment Management Co. LLC now owns 3,488,863 shares of the biopharmaceutical company’s stock valued at $33,842,000 after buying an additional 628,438 shares during the last quarter. Jennison Associates LLC raised its position in shares of Amicus Therapeutics by 3.3% in the fourth quarter. Jennison Associates LLC now owns 4,123,955 shares of the biopharmaceutical company’s stock valued at $40,002,000 after buying an additional 133,138 shares during the last quarter. California Public Employees Retirement System raised its position in shares of Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 11,600 shares during the last quarter. Swiss National Bank raised its position in shares of Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares during the last quarter. Finally, Nationwide Fund Advisors raised its position in shares of Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,754 shares during the last quarter.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.